Coplanar polychlorinated biphenyl-induced CYP1A1 is regulated through caveolae signaling in vascular endothelial cells.
Polychlorinated biphenyls (PCBs) are persistent environmental contaminants that can induce inflammatory processes in the vascular endothelium. We hypothesize that the plasma membrane microdomains called caveolae are critical in endothelial activation and toxicity induced by PCBs. Caveolae are particularly abundant in endothelial cells and play a major role in endothelial trafficking and the regulation of signaling pathways associated with the pathology of vascular diseases. We focused on the role of caveolae and their major protein component, caveolin-1 (Cav-1), on aryl hydrocarbon receptor (AhR)-mediated induction of cytochrome P450 1A1 (CYP1A1) by coplanar PCBs. Endothelial cell exposure to PCB77 increased both caveolin-1 and CYP1A1 levels in a time-dependent manner in total cell lysates, with a maximum increase at 6h. Furthermore, PCB77 accumulated mainly in the caveolae-rich fraction, as determined by gas chromatograph-mass spectrometry. Immunoprecipitation analysis revealed that PCB77 increased AhR binding to caveolin-1. Silencing of caveolin-1 significantly attenuated PCB77-mediated induction of CYP1A1 and oxidative stress. Similar effects were observed in caveolin-1 null mice treated with PCB77. These data suggest that caveolae may play a role in regulating vascular toxicity induced by persistent environmental pollutants such as coplanar PCBs. This may have implications in understanding mechanisms of inflammatory diseases induced by environmental pollutants.
Lim
Eun Jin
EJ
Molecular and Cell Nutrition Laboratory, Department of Chemistry, College of Agriculture, University of Kentucky, Lexington, KY 40536, USA.
Májková
Zuzana
Z
Xu
Shifen
S
Bachas
Leonidas
L
Arzuaga
Xabier
X
Smart
Eric
E
Tseng
Michael T
MT
Toborek
Michal
M
Hennig
Bernhard
B
D000818:Animals; D021941:Caveolae / Q000187:drug effects* / Q000378:metabolism*; D051242:Caveolin 1 / Q000172:deficiency / Q000378:metabolism; D002478:Cells, Cultured; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D008297:Male; D051379:Mice; D008819:Mice, Nude; D018384:Oxidative Stress / Q000187:drug effects; D011078:Polychlorinated Biphenyls / Q000494:pharmacology*; D018336:Receptors, Aryl Hydrocarbon / Q000378:metabolism; D011973:Receptors, LDL / Q000172:deficiency / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D013997:Time Factors
D051242:Caveolin 1; D018336:Receptors, Aryl Hydrocarbon; D011973:Receptors, LDL; D011078:Polychlorinated Biphenyls; D019363:Cytochrome P-450 CYP1A1; C023035:3,4,5,3',4'-pentachlorobiphenyl; C028451:3,4,3',4'-tetrachlorobiphenyl
Toxicol Appl Pharmacol. 2002 Jun 15;181(3):174-83
12079426
Handb Exp Pharmacol. 2006;(176 Pt 1):107-44
16999218
Trends Cardiovasc Med. 2005 Apr;15(3):92-6
16039968
J Biol Chem. 1999 Nov 19;274(47):33551-6
10559241
Cardiovasc Res. 2006 Apr 1;70(1):31-41
16540099
Mol Cell Endocrinol. 2005 Dec 21;245(1-2):128-37
16368181
Mol Cell Biol. 1999 Nov;19(11):7289-304
10523618
Biochim Biophys Acta. 2006 Apr;1761(4):416-23
16702023
Mol Endocrinol. 2002 Jan;16(1):100-15
11773442
Nutr Metab Cardiovasc Dis. 2003 Apr;13(2):104-13
12929624
Biochem Pharmacol. 2003 Aug 15;66(4):527-40
12906918
J Biol Chem. 1996 Apr 19;271(16):9690-7
8621645
Science. 2001 Sep 28;293(5539):2449-52
11498544
Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1161-8
12689915
Biochim Biophys Acta. 2005 Dec 30;1746(3):334-48
16214243
Environ Health Perspect. 2008 Jun;116(6):761-8
18560532
Environ Health Perspect. 2005 Jan;113(1):83-7
15626652
Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):98-105
14563650
J Biochem Toxicol. 1995 Aug;10(4):219-26
8568836
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3340-7
17933968
Am J Ind Med. 1997 Sep;32(3):234-9
9219652
N Engl J Med. 1999 Jan 14;340(2):115-26
9887164
Adv Drug Deliv Rev. 2001 Jul 28;49(3):237-50
11551397
Annu Rev Pharmacol Toxicol. 1999;39:103-25
10331078
Exp Cell Res. 1999 Dec 15;253(2):629-36
10585286
Brain Res. 1999 Jun 26;833(1):121-4
10375686
Biochem Biophys Res Commun. 2005 Nov 25;337(3):849-52
16225848
Mol Pharmacol. 1995 Feb;47(2):296-306
7870038
Mol Biol Cell. 2004 Jan;15(1):99-110
14528016
Biochim Biophys Acta. 2005 Dec 30;1746(3):322-33
16019085
J Biol Chem. 2001 Apr 20;276(16):13442-51
11278309
Environ Toxicol Pharmacol. 2008 Mar;25(2):251-9
18438459
Curr Opin Nephrol Hypertens. 2007 Mar;16(2):90-104
17293683
Toxicol Sci. 2003 Nov;76(1):212-9
12970578
Arteriosclerosis. 1984 Sep-Oct;4(5):489-97
6477300
Cardiovasc Toxicol. 2004;4(4):363-73
15531779
J Biochem Mol Toxicol. 1999;13(2):83-91
9890193
Ann N Y Acad Sci. 1997 Dec 26;837:138-56
9472337
Biochim Biophys Acta. 2003 Mar 10;1610(2):219-28
12648776
Environ Health Perspect. 2005 Jun;113(6):756-61
15929900
Cardiovasc Res. 2006 Apr 1;70(1):42-9
16412403
J Biol Chem. 1998 Feb 6;273(6):3125-8
9452418
Arch Toxicol Suppl. 1995;17:99-115
7786196
Toxicol Appl Pharmacol. 2008 Oct 15;232(2):309-16
18671994
Aquat Toxicol. 2006 May 25;77(4):422-32
16500718